{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:57:49Z","timestamp":1789909069028,"version":"4.0.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,2,2]],"date-time":"2017-02-02T00:00:00Z","timestamp":1485993600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100012638","name":"Valerion Therapeutics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012638","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s00109-017-1505-9","type":"journal-article","created":{"date-parts":[[2017,2,2]],"date-time":"2017-02-02T14:13:08Z","timestamp":1486044788000},"page":"513-521","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease"],"prefix":"10.1007","volume":"95","author":[{"given":"Haiqing","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Borneman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Austin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya S.","family":"Kishnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2191-0025","authenticated-orcid":false,"given":"Baodong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,2]]},"reference":[{"issue":"9646","key":"1505_CR1","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","volume":"372","author":"AT Ploeg van der","year":"2008","unstructured":"van der Ploeg AT, Reuser AJ (2008) Pompe\u2019s disease. Lancet 372(9646):1342\u20131353","journal-title":"Lancet"},{"issue":"5","key":"1505_CR2","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","volume":"148","author":"PS Kishnani","year":"2006","unstructured":"Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D (2006) A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 148(5):671\u2013676","journal-title":"J Pediatr"},{"issue":"9\u201310","key":"1505_CR3","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.nmd.2007.06.002","volume":"17","author":"W Muller-Felber","year":"2007","unstructured":"Muller-Felber W, Horvath R, Gempel K, Podskarbi T, Shin Y, Pongratz D, Walter MC, Baethmann M, Schlotter-Weigel B, Lochmuller H et al (2007) Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients. Neuromuscul Disord 17(9\u201310):698\u2013706","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"1505_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ajmg.c.31324","volume":"160","author":"PS Kishnani","year":"2012","unstructured":"Kishnani PS, Beckemeyer AA, Mendelsohn NJ (2012) The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management. Am J Med Genet C Semin Med Genet 160(1):1\u20137","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"1","key":"1505_CR5","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11910-011-0236-5","volume":"12","author":"C Angelini","year":"2012","unstructured":"Angelini C, Semplicini C (2012) Enzyme replacement therapy for Pompe disease. Curr Neurol Neurosci Rep 12(1):70\u201375","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"1","key":"1505_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ajmg.c.31321","volume":"160","author":"LE Case","year":"2012","unstructured":"Case LE, Beckemeyer AA, Kishnani PS (2012) Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations. Am J Med Genet C Semin Med Genet 160(1):69\u201379","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"1","key":"1505_CR7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1073\/pnas.93.1.65","volume":"93","author":"JL Hove Van","year":"1996","unstructured":"Van Hove JL, Yang HW, Wu JY, Brady RO, Chen YT (1996) High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease. Proc Natl Acad Sci U S A 93(1):65\u201370","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1505_CR8","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/0002-9343(68)90160-5","volume":"44","author":"JC Garancis","year":"1968","unstructured":"Garancis JC (1968) Type II glycogenosis. Biochemical and electron microscopic study. Am J Med 44(2):289\u2013300","journal-title":"Am J Med"},{"issue":"12","key":"1505_CR9","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/labinvest.3700484","volume":"86","author":"BL Thurberg","year":"2006","unstructured":"Thurberg BL, Lynch Maloney C, Vaccaro C, Afonso K, Tsai AC, Bossen E, Kishnani PS, O\u2019Callaghan M (2006) Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. Lab Invest 86(12):1208\u20131220","journal-title":"Lab Invest"},{"issue":"2","key":"1505_CR10","first-page":"123","volume":"46","author":"E Lewandowska","year":"2008","unstructured":"Lewandowska E, Wierzba-Bobrowicz T, Rola R, Modzelewska J, Stepien T, Lugowska A, Pasennik E, Ryglewicz D (2008) Pathology of skeletal muscle cells in adult-onset glycogenosis type II (Pompe disease): ultrastructural study. Folia Neuropathol 46(2):123\u2013133","journal-title":"Folia Neuropathol"},{"issue":"1","key":"1505_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/BF02889849","volume":"45","author":"JL Griffin","year":"1984","unstructured":"Griffin JL (1984) Infantile acid maltase deficiency. I. Muscle fiber destruction after lysosomal rupture. Virchows Arch B Cell Pathol Incl Mol Pathol 45(1):23\u201336","journal-title":"Virchows Arch B Cell Pathol Incl Mol Pathol"},{"issue":"10","key":"1505_CR12","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.2174\/1389450117666151209120139","volume":"17","author":"K Rehman","year":"2016","unstructured":"Rehman K, Hamid Akash MS, Akhtar B, Tariq M, Mahmood A, Ibrahim M (2016) Delivery of therapeutic proteins: challenges and strategies. Curr Drug Targets 17(10):1172\u20131188","journal-title":"Curr Drug Targets"},{"key":"1505_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2016.06.002","author":"A Komin","year":"2016","unstructured":"Komin A, Russell LM, Hristova KA, Searson PC (2016) Peptide-based strategies for enhanced cell uptake, transcellular transport, and circulation: mechanisms and challenges. Adv Drug Deliv Rev. doi: 10.1016\/j.addr.2016.06.002","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"1505_CR14","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.4049\/jimmunol.157.5.2082","volume":"157","author":"DJ Zack","year":"1996","unstructured":"Zack DJ, Stempniak M, Wong AL, Taylor C, Weisbart RH (1996) Mechanisms of cellular penetration and nuclear localization of an anti-double strand DNA autoantibody. J Immunol 157(5):2082\u20132088","journal-title":"J Immunol"},{"issue":"1","key":"1505_CR15","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.brainres.2006.03.025","volume":"1088","author":"JE Hansen","year":"2006","unstructured":"Hansen JE, Sohn W, Kim C, Chang SS, Huang NC, Santos DG, Chan G, Weisbart RH, Nishimura RN (2006) Antibody-mediated Hsp70 protein therapy. Brain Res 1088(1):187\u2013196","journal-title":"Brain Res"},{"issue":"5","key":"1505_CR16","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1006\/jaut.1998.0212","volume":"11","author":"RH Weisbart","year":"1998","unstructured":"Weisbart RH, Stempniak M, Harris S, Zack DJ, Ferreri K (1998) An autoantibody is modified for use as a delivery system to target the cell nucleus: therapeutic implications. J Autoimmun 11(5):539\u2013546","journal-title":"J Autoimmun"},{"issue":"8","key":"1505_CR17","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1093\/hmg\/ddt003","volume":"22","author":"MW Lawlor","year":"2013","unstructured":"Lawlor MW, Armstrong D, Viola MG, Widrick JJ, Meng H, Grange RW, Childers MK, Hsu CP, O\u2019Callaghan M, Pierson CR et al (2013) Enzyme replacement therapy rescues weakness and improves muscle pathology in mice with X-linked myotubular myopathy. Hum Mol Genet 22(8):1525\u20131538","journal-title":"Hum Mol Genet"},{"issue":"29","key":"1505_CR18","doi-asserted-by":"publisher","first-page":"20790","DOI":"10.1074\/jbc.C700090200","volume":"282","author":"JE Hansen","year":"2007","unstructured":"Hansen JE, Tse CM, Chan G, Heinze ER, Nishimura RN, Weisbart RH (2007) Intranuclear protein transduction through a nucleoside salvage pathway. J Biol Chem 282(29):20790\u201320793","journal-title":"J Biol Chem"},{"issue":"3","key":"1505_CR19","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1006\/bbrc.2000.4205","volume":"280","author":"M Pennycooke","year":"2001","unstructured":"Pennycooke M, Chaudary N, Shuralyova I, Zhang Y, Coe IR (2001) Differential expression of human nucleoside transporters in normal and tumor tissue. Biochem Biophys Res Commun 280(3):951\u2013959","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"1505_CR20","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1124\/dmd.104.001123","volume":"32","author":"H Lu","year":"2004","unstructured":"Lu H, Chen C, Klaassen C (2004) Tissue distribution of concentrative and equilibrative nucleoside transporters in male and female rats and mice. Drug Metab Dispos 32(12):1455\u20131461","journal-title":"Drug Metab Dispos"},{"issue":"30","key":"1505_CR21","doi-asserted-by":"publisher","first-page":"19086","DOI":"10.1074\/jbc.273.30.19086","volume":"273","author":"N Raben","year":"1998","unstructured":"Raben N, Nagaraju K, Lee E, Kessler P, Byrne B, Lee L, LaMarca M, King C, Ward J, Sauer B et al (1998) Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. J Biol Chem 273(30):19086\u201319092","journal-title":"J Biol Chem"},{"issue":"3","key":"1505_CR22","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1074\/jbc.M112.438663","volume":"288","author":"JA Maga","year":"2013","unstructured":"Maga JA, Zhou J, Kambampati R, Peng S, Wang X, Bohnsack RN, Thomm A, Golata S, Tom P, Dahms NM et al (2013) Glycosylation-independent lysosomal targeting of acid alpha-glucosidase enhances muscle glycogen clearance in Pompe mice. J Biol Chem 288(3):1428\u20131438","journal-title":"J Biol Chem"},{"issue":"1","key":"1505_CR23","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/j.1365-2249.2008.03602.x","volume":"152","author":"A Joseph","year":"2008","unstructured":"Joseph A, Munroe K, Housman M, Garman R, Richards S (2008) Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model. Clin Exp Immunol 152(1):138\u2013146","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"1505_CR24","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/j.1365-2362.1974.tb02358.x","volume":"4","author":"P Hallgren","year":"1974","unstructured":"Hallgren P, Hansson G, Henriksson KG, Hager A, Lundblad A, Svensson S (1974) Increased excretion of a glucose-containing tetrasaccharide in the urine of a patient with glycogen storage disease type II (Pompe\u2019s disease). Eur J Clin Invest 4(6):429\u2013433","journal-title":"Eur J Clin Invest"},{"issue":"6","key":"1505_CR25","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1242\/dmm.009712","volume":"5","author":"H Yi","year":"2012","unstructured":"Yi H, Thurberg BL, Curtis S, Austin S, Fyfe J, Koeberl DD, Kishnani PS, Sun B (2012) Characterization of a canine model of glycogen storage disease type IIIa. Dis Model Mech 5(6):804\u2013811","journal-title":"Dis Model Mech"},{"issue":"16","key":"1505_CR26","doi-asserted-by":"publisher","first-page":"8861","DOI":"10.1073\/pnas.96.16.8861","volume":"96","author":"A Amalfitano","year":"1999","unstructured":"Amalfitano A, McVie-Wylie AJ, Hu H, Dawson TL, Raben N, Plotz P, Chen YT (1999) Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase. Proc Natl Acad Sci U S A 96(16):8861\u20138866","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1505_CR27","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0003-2697(03)00056-3","volume":"316","author":"SP Young","year":"2003","unstructured":"Young SP, Stevens RD, An Y, Chen YT, Millington DS (2003) Analysis of a glucose tetrasaccharide elevated in Pompe disease by stable isotope dilution-electrospray ionization tandem mass spectrometry. Anal Biochem 316(2):175\u2013180","journal-title":"Anal Biochem"},{"issue":"3","key":"1505_CR28","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.ymgme.2013.05.004","volume":"109","author":"H Yi","year":"2013","unstructured":"Yi H, Fredrickson KB, Das S, Kishnani PS, Sun B (2013) Stbd1 is highly elevated in skeletal muscle of Pompe disease mice but suppression of its expression does not affect lysosomal glycogen accumulation. Mol Genet Metab 109(3):312\u2013314","journal-title":"Mol Genet Metab"},{"issue":"8","key":"1505_CR29","doi-asserted-by":"publisher","first-page":"6780","DOI":"10.1074\/jbc.M404008200","volume":"280","author":"RJ Moreland","year":"2005","unstructured":"Moreland RJ, Jin X, Zhang XK, Decker RW, Albee KL, Lee KL, Cauthron RD, Brewer K, Edmunds T, Canfield WM (2005) Lysosomal acid alpha-glucosidase consists of four different peptides processed from a single chain precursor. J Biol Chem 280(8):6780\u20136791","journal-title":"J Biol Chem"},{"issue":"1\u20132","key":"1505_CR30","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ymgme.2003.08.022","volume":"80","author":"N Raben","year":"2003","unstructured":"Raben N, Danon M, Gilbert AL, Dwivedi S, Collins B, Thurberg BL, Mattaliano RJ, Nagaraju K, Plotz PH (2003) Enzyme replacement therapy in the mouse model of Pompe disease. Mol Genet Metab 80(1\u20132):159\u2013169","journal-title":"Mol Genet Metab"},{"issue":"5","key":"1505_CR31","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S1525-0016(02)90716-1","volume":"6","author":"N Raben","year":"2002","unstructured":"Raben N, Jatkar T, Lee A, Lu N, Dwivedi S, Nagaraju K, Plotz PH (2002) Glycogen stored in skeletal but not in cardiac muscle in acid alpha-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme. Mol Ther 6(5):601\u2013608","journal-title":"Mol Ther"},{"issue":"10","key":"1505_CR32","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/jgm.1372","volume":"11","author":"B Sun","year":"2009","unstructured":"Sun B, Zhang H, Bird A, Li S, Young SP, Koeberl DD (2009) Impaired clearance of accumulated lysosomal glycogen in advanced Pompe disease despite high-level vector-mediated transgene expression. J Gene Med 11(10):913\u2013920","journal-title":"J Gene Med"},{"issue":"13","key":"1505_CR33","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1039\/b719950c","volume":"6","author":"KM Stewart","year":"2008","unstructured":"Stewart KM, Horton KL, Kelley SO (2008) Cell-penetrating peptides as delivery vehicles for biology and medicine. Org Biomol Chem 6(13):2242\u20132255","journal-title":"Org Biomol Chem"},{"issue":"7","key":"1505_CR34","doi-asserted-by":"publisher","first-page":"13313","DOI":"10.3390\/molecules200713313","volume":"20","author":"T Skotland","year":"2015","unstructured":"Skotland T, Iversen TG, Torgersen ML, Sandvig K (2015) Cell-penetrating peptides: possibilities and challenges for drug delivery in vitro and in vivo. Molecules 20(7):13313\u201313323","journal-title":"Molecules"},{"issue":"6","key":"1505_CR35","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1021\/mp100223d","volume":"7","author":"D Sarko","year":"2010","unstructured":"Sarko D, Beijer B, Garcia Boy R, Nothelfer EM, Leotta K, Eisenhut M, Altmann A, Haberkorn U, Mier W (2010) The pharmacokinetics of cell-penetrating peptides. Mol Pharm 7(6):2224\u20132231","journal-title":"Mol Pharm"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-017-1505-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00109-017-1505-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-017-1505-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T01:37:00Z","timestamp":1692668220000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00109-017-1505-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,2]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["1505"],"URL":"https:\/\/doi.org\/10.1007\/s00109-017-1505-9","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,2]]}}}